ARPA-H launched a program called ADVOCATE to build FDA-authorized agentic AI tools for care in heart disease. UpDoc, Tempus AI, and Atman Health were selected to participate, with the government framing the effort as a pathway to deploy clinically usable AI under regulatory conditions. The initiative follows federal emphasis on patient-impacting AI systems that meet authorization standards rather than remaining limited to research prototypes. The selected companies bring mix-and-match assets across clinical data, workflow integration and analytics. For biotech-adjacent technology firms, the award is another signal that AI commercialization is increasingly tied to a regulatory execution plan—especially around safety, transparency and data governance.